File downloaded on 2026-11-12
Source URL: https://medicines.health.europa.eu/veterinary/en/600000027673

Imoxat 250 mg + 62.5 mg - Spot-on solution

Authorised

- Moxidectin
- Imidacloprid

Product identification

Medicine name:
Imoxat 250 mg + 62.5 mg - Spot-on solution

Active substance:
Moxidectin

Imidacloprid

Target species:
Dog

Route of administration:
Spot-on use

Product details

Active substance and strength:
Moxidectin

Presentation_strength:62.5 mg Reference:Hse Index:0
Imidacloprid

Presentation_strength:250 mg Reference:Hse Index:1

Pharmaceutical form:
Spot-on solution

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QP54AB52

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Package description:
Packaging:Pipette (PP/COC/EVOH/PP), Package_size:1 pipette, Content:2.5 ml
Packaging:Pipette (PP/COC/EVOH/PP), Package_size:3 pipettes, Content:2.5 ml

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
Chanelle Pharmaceuticals Manufacturing Limited

Marketing authorisation date:
7/12/2021

Manufacturing sites for batch release:
Chanelle Pharmaceuticals Manufacturing Limited

Responsible authority:
European Commission

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
7/12/2021

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 13/03/2026
Download

ema-puar-imoxat-v-5597-par-en.pdf